Pierre Fabre
New ways to care  

From 100 to 600 patients: to support patients suffering from acne, Avène, Pierre Fabre Laboratories’ leading brand, is strengthening the robustness of its clinical studies via data augmentation through Artificial Intelligence. Toulouse, February 19, 2026 – Avène, the leading brand in French pharmacies*, in partnership with Toulouse-based HealthTech company BotDesign, has announced a major breakthrough in the field of clinical studies in dermo-cosmetics. In 2026, Avène will conduct a comparative clinical study to evaluate the efficacy of its new treatment for acne-prone skin, Avène Cleanance Comedomed+, in the maintenance phase following oral isotretinoin treatment in adults suffering from severe to very severe acne. Avène is renowned for its dermatological expertise, inspired by therapeutic know-how, and has been committed to improving the treatment of skin pathologies since 1990. It is thus becoming the first brand to use Artificial Intelligence in clinical studies for dermo-cosmetics.

On the occasion of World Cancer Day, the 2026 Gustave Roussy Prize was awarded to Prof. Luis Diaz Jr., an international figure in oncology whose work has transformed the care of thousands of patients worldwide. As the founding patron of the Prize, Pierre Fabre salutes a major scientific breakthrough and reaffirms its commitment alongside the research teams shaping the future of precision medicine.

Castres, January 29, 2026 - Emmanuelle HOCQUARD de KERLEAU has been appointed Chief Impact and Reputation Officer at Pierre Fabre Laboratories, which owns a portfolio of international dermo-cosmetic brands including Eau Thermale Avène, Ducray, Klorane, A-Derma, René Furterer, as well as a Medical Care business covering five main therapeutic areas: oncology, dermatology, rare diseases, chronic diseases, and family health care. Emmanuelle de KERLEAU will be responsible for designing and implementing integrated corporate social responsibility (CSR), corporate communications and public affairs strategies to strengthen the positive impact of Pierre Fabre Laboratories among all its key stakeholders. She will oversee all activities currently carried out by the Corporate Communications and CSR (Green Mission Pierre Fabre) departments.   Marc ALIAS, Director of Corporate Communications, will leave the company at the end of a transition period running until April 2026. The company would like to express its deep gratitude for his leadership at the head of the Communications Department over the past fifteen years. He has left a lasting mark on the identity and reputation of the corporate brand, whose relaunch he orchestrated with the new slogan "Laboratoires Pierre Fabre, New Ways to Care." About Emmanuelle de KERLEAU Emmanuelle de KERLEAU is a lawyer by training. She began her career in 1998 at the law firm Alain Bensoussan Avocats, before contributing to the creation of the start-up Webhelp. After a period at Arthur Andersen, she joined Federal Express, where she headed the Public Affairs and Legal Department for Europe from 2003 to 2011, while developing the company’s first CSR roadmap.  In 2012, Emmanuelle joined Coca-Cola Enterprises as Vice President of Public Affairs, Communications, and CSR for France. In this role, she led the company's repositioning as a local player and trusted partner, deploying a strategy that integrated CSR at the core of the company's business priorities and reputation building.  In 2022, she was appointed Vice President of Public Affairs and Advocacy at Coca-Cola EuroPacific Partners. She created a public affairs function deployed in 30 countries and redefined the advocacy strategy of the world's largest Coca-Cola bottler.   Deeply committed to aligning corporate communications, CSR, and business objectives in both French and international context, Emmanuelle firmly believes in the importance of companies generating a positive social and environmental impact.Emmanuelle is involved in various non-profit organizations and serves on the Board of Directors of Special Olympics France, an association working to change perceptions of mental disability and to facilitate access to healthcare for people with intellectual disabilities.

Castres, France, and Paris, France, January 9th – Pierre Fabre Laboratories and Iktos, a global leader in Artificial Intelligence (AI) and Robotics on drug discovery, today announced an integrated drug discovery collaboration to identify and develop novel small-molecule drug candidates in oncology. This initiative reflects both companies’ commitment to advancing oncology research by integrating complementary strengths across computational design, medicinal chemistry, biology, medical science and preclinical development.

Paris, December 18, 2025 – Pierre Fabre Laboratories are proud to announce that they have received the Grand Prix FAS for Employee Shareholding, the highest distinction awarded by the French Federation of Employee Shareholding (FAS). This recognition highlights our ongoing commitment and leadership in employee shareholding, an essential pillar of our corporate strategy.